

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Kellner's Symptom Questionnaire, a Highly Sensitive Patient-Reported Outcome Measure: Systematic Review of Clinimetric Properties

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Benasi G., Fava G.A., Rafanelli C. (2020). Kellner's Symptom Questionnaire, a Highly Sensitive Patient-Reported Outcome Measure: Systematic Review of Clinimetric Properties. *PSYCHOTHERAPY AND PSYCHOSOMATICS*, 89(2), 74-89 [10.1159/000506110].

Availability:

This version is available at: <https://hdl.handle.net/11585/803330> since: 2022-11-24

Published:

DOI: <http://doi.org/10.1159/000506110>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

**Kellner's Symptom Questionnaire, A Highly Sensitive Patient-Reported Outcome Measure.
Systematic Review of Clinimetric Properties**

Giada Benasi¹, Giovanni A. Fava² and Chiara Rafanelli¹

¹ Department of Psychology, University of Bologna, Bologna, Italy

² Department of Psychiatry, University at Buffalo, State University of New York, Buffalo, N.Y.

running title: Symptom Questionnaire

Correspondence: Chiara Rafanelli, M.D.,Ph.D., Department of Psychology, University of Bologna, viale Berti Pichat 5, 40127 Bologna, Italy. chiara.rafanelli@unibo.it

ABSTRACT

Introduction: Patient-reported outcomes (PROs) are of increasing importance in clinical medicine. Their evaluation by classic psychometric methods, however, carries considerable limitations. The clinimetric approach provides a viable framework for their assessment.

Objective: The aim of this paper was to provide a systematic review of clinimetric properties of the Symptom Questionnaire (SQ), a simple, self-rated instrument for the assessment of psychological symptoms (depression, anxiety, hostility, and somatization) and well-being (contentment, relaxation, friendliness, and physical well-being).

Methods: The PRISMA guidelines were used. Electronic databases were searched from inception up to March 2019. Only original research articles, published in English, reporting data about the clinimetric properties of the SQ, were included.

Results: A total of 284 studies was selected. The SQ has been used in populations of adults, adolescents, and older individuals. The scale significantly discriminated between subgroups of subjects in both clinical and non-clinical settings, and differentiated medical and psychiatric patients from healthy controls. In longitudinal studies and in controlled pharmacological and psychotherapy trials, it was highly sensitive to symptoms and well-being changes and discriminated between the effects of psychotropic drugs and placebo.

Conclusions: The SQ is a highly sensitive clinimetric index. It may yield clinical information that similar scales would fail to provide and has a unique position among the PROs that are available. Its use in clinical trials is strongly recommended.

Key-words: Symptom Questionnaire; Patient-reported outcome; Self-rating scale; Clinimetrics; Clinical pharmacopsychology; Anxiety; Depression; Somatization; Hostility; Psychological well-being.

Introduction

Patient reported outcomes (PROs), any report coming directly from patients about how they function or feel in relation to a health condition or its therapy, are of increasing importance in clinical medicine and psychology [1]. Some PROs focus on self-rated evaluation of specific disease-related conditions, such as cancer, pain, or depression [1,2]. Other indices are focused on more general perceptions, such as quality of life and psychological well-being [3–5].

In clinical psychology, the use of self-rating scales for evaluating the psychological status in conjunction or alternative to observer-rated methods has paved the ground for the developments of PROs [3,6]. In psychiatry, self-rating scales, long before the appearance of PROs, have been part of assessment tools for clinical trials [7]. Guidelines for inclusion of PROs in clinical trial protocols have been recently developed [8]. However, the application of the classical psychometric model to the clinical challenges appears to be inadequate [9,10]. The homogeneity of items, as measured by statistical tests such as Cronbach's alpha, has often been the most important requirement for a rating scale [10]. However, the same properties that give a scale a high score for internal consistency may obscure its ability to detect change. The redundant nature of the items of a scale may increase Cronbach's alpha, but decrease its sensitivity [10]. The ability of a rating scale to discriminate between different groups of patients suffering from the same illness (e.g., depressed inpatients and outpatients) and to reflect changes in experiments in therapeutics such as drug trials has been defined by Kellner [11] as sensitivity. Scales may be valid and reliable, but may lack sensitivity. This is particularly important when treatment effects are small and with limited sample sizes. The concept of sensitivity refers to both the detection of psychological states (whether symptoms or well-being) and their changes with treatment.

In 1982, Alvan Feinstein [12] introduced the term clinimetrics, to indicate a domain concerned with the measurement of clinical issues that do not find room in customary clinical taxonomy. Clinimetrics has a set of rules which govern the structure of indices, the choice of component variables, the evaluation of consistency and validity, and that differ from classical psychometrics, which developed outside the clinical field, mainly in the educational and social areas [9,10,13–15].

The Symptom Questionnaire (SQ) is a simple, self-rated questionnaire that was developed by Robert Kellner in 1976 [16] and can be used for the assessment of both symptoms and well-being. Its psychometric properties have been outlined by the Author in a paper published more than 30 years ago [17]. The aim of this paper is to update this work and provide a comprehensive review of clinimetric properties of the SQ.

Development and Characteristics of the SQ

The SQ was developed by Robert Kellner with the aim of providing a scale to be used in clinical research that could be more sensitive than other instruments [17].

The SQ was originated from the Symptom Rating Test (SRT) [18], a self-rating scale specifically designed to measure changes in distress among neurotic patients participating in efficacy trials, such as drug trials. The design principles of the SQ were therefore those of a distress scale, and its items were derived from the same list of neurotic symptoms used to create the SRT.

Nevertheless, the SQ has had a long evolution [16] and each stage in its development was based on empirical findings [17]. The SQ anxiety, depression, and somatization scales were created from a review of the literature on factor analyses of symptoms of psychiatric patients and normal controls. Items were included in the final version of these scales based on their ability to discriminate between depressed and anxious nonpsychotic psychiatric patients and normal subjects, and between psychotropic drug and placebo in three drug trials [17]. The hostility scale was constructed according to a clinimetric approach. Statements that two investigators agreed to consider as expression of anger or hostility were selected from interviews with patients with neurotic or personality disorders. Items were retained in the final version of the scale if they were reported significantly more frequently by hostile patients compared with normal subjects or patients judged to be not hostile in two studies. Furthermore, the literature on factor analyses of symptoms in psychiatric patients and normal subjects was searched, and items were retained if they were part of a factor of anger, hostility, or irritability [17].

The SQ differs from the SRT in that it has brief items instead of questions, and yes/no or true/false responses instead of scales of severity or frequency of symptoms. The total number of items was increased and statements of well-being were included in order to improve the sensitivity of the scale [19,20].

Description

The final version of the SQ consists of 92 items and yields 4 main scales: depression, anxiety, hostility, and somatization scales (see **Appendix 1, Online Supplementary Material**). Each scale can be divided into two subscales, one concerned with symptoms and the other with well-being, for a total of 8 subscales. Therefore, each of the main scales includes items from both the symptoms and the well-being subscales (**Table 1**).

Answers are dichotomous and the respondent is asked to check YES/NO or TRUE/FALSE for each item. Scales and subscales can be scored separately, and the sum of the four main scales scores yields to a total distress score. Instructions for scoring are reported in **Appendix 2 (Online Supplementary Material)**. Norms for the interpretation of results are available in Kellner [17]. Moderate distress is

indicated by a scale score between 1 and 2 standard deviations above the mean for normal subjects, while severe distress or psychopathology are suggested by a scale score of 2 standard deviations above the mean. A single high score in one or more of the SQ scales is not enough to make a diagnosis of psychopathology and further clinical assessment is required. In particular, a high score on the somatization scale needs to be interpreted with caution when a medical disease is present.

Two forms of the SQ are available, which differ only for a different time focus. The week form is concerned with feelings experienced by the respondent during the past week, while the day form with feelings experienced on the day of the test. These two forms may serve different purposes in research. The week form is the most commonly used [17].

Clinical applications

The SQ has been translated into several languages, such as Italian, French, German, Spanish, Portuguese, Dutch, Urdu, Punjabi, Cantonese, Mandarin, Arabic dialects, Russian, Swedish, and Hindi. Most of the studies in which the SQ was administered were performed in Italy, the US, Canada, and the UK. In these studies, the SQ has been used to assess levels of distress and well-being across clinical and non-clinical populations, and as an outcome variable to test the efficacy of pharmacological and psychological interventions. In longitudinal studies, the scale has been used to detect significant changes in symptomatology. Moreover, several studies were concerned with the relationship with other rating scales or constructs.

Methods

Search strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [21] were used to perform the present systematic review.

The search was carried out from inception until March 2019 in the following databases: PubMed, PsycINFO, and MEDLINE, KCI-Korean Journal Database, Russian Science Citation Index, and SciELO citation index via Web of Science. In each database the key words “Symptom Questionnaire”, “SQ”, and “Kellner” were used.

The databases SCOPUS and Web of Science were consulted for articles citing the work “A Symptom Questionnaire” of Kellner [17], that is the main reference for the SQ. The reference lists of the retrieved articles were also examined for additional studies.

Study selection

Only articles published in English and reporting data about the clinimetric properties of the SQ were selected. A first screening of titles and abstracts was performed to exclude articles published in a language other than English, non-original research articles (e.g., books, meeting abstracts, letters, commentaries, reviews, etc.), and papers that were clearly irrelevant. The full texts of the remaining papers were analyzed.

The search, selection, and analysis of the selected studies were performed independently by two reviewers (G.B. and C.R.); disagreements were resolved by consensus among these primary raters and a senior investigator (G.A.F.).

Data extraction

Data were independently extracted by both reviewers with the use of a precoded form. The following data were extracted from studies meeting criteria for inclusion in the systematic review: country and field in which the study was performed; sample characteristics and size; measures and statistical analyses; clinimetric data.

Results

A total of 284 studies were included in the review (**Figure 1, Online Supplementary Material**). Of these, 232 research articles were found to display the clinimetric properties of the SQ and are included in the present review. Other papers in which the SQ was used will not be discussed in detail (see **Additional references, Online Supplementary Material**).

Specifically, we focused on data about discriminant validity, sensitivity to change, concurrent and divergent validity, relations to other dimensions and biomarkers, and predictive validity. The differential sensitivity of the SQ compared to other scales, and differences between symptoms and well-being subscales, have been highlighted and discussed.

Discriminant validity

Patients versus controls

Most of the SQ scales and subscales were able to significantly discriminate in the expected direction between psychiatric patients and controls [22–41]. In some of these studies, the SQ showed particularly high discriminant validity, being able to sensitively differentiate remitted patients with residual affective symptoms from healthy subjects [24,29–31,40,41].

In several studies, the SQ scores were also able to differentiate medical patients from healthy controls. In all of these studies, levels of distress and well-being were significantly worse among family

practice patients [25,35], breast cancer survivors [42], and patients affected by endocrine [43–50] and gastrointestinal [51,52] conditions than among healthy subjects.

In two studies, the SQ was administered to a sample of adolescents and significantly discriminated between those with or without epilepsy [53] or endocrine disorders [54].

Different groups of patients and healthy subjects

The SQ has been used in many clinical investigations to discriminate between subgroups of patients across different medical and psychiatric settings.

In psychiatry, the SQ significantly discriminated between subgroups of patients with affective disorders [22,25,27,28,37,55–63] or post-traumatic stress disorder [64,65].

Most of the SQ scales and subscales were able to discriminate between different subgroups of medical patients in cardiology [66–87], endocrinology [43–47,50,88], oncology [42,89–93], dermatology [94], gynecology [95–100], pneumology [101], and general medical settings [102–104], based on the presence of specific medical or psychological features and comorbidities.

In two studies comparing psychiatric and medical patients with each other, the SQ scores were significantly worse among psychiatric patients than among patients in family practice [25,35].

The SQ has been used in a variety of other studies to discriminate between subgroups of healthy subjects. In some of these studies, the scale allowed the identification of significant differences in levels of distress and well-being among subjects facing with different sources of distress, such as illness of a family member [105–108], the occurrence of a major life event [109,110], and exposure to childhood maltreatment [111–118] or intimate partner violence [119,120]. In other two studies, the SQ discriminated between personality clusters among parents of patients with eating disorders [121], and between law and medical students [122].

There were no clear indications for gender differences in levels of distress and well-being assessed by the SQ [28,84,91,105,122–128].

Symptoms versus well-being subscales

Except for two studies, in which the well-being subscales appeared to discriminate more sensitively between patients and controls [38,47], most of the symptoms subscales were more sensitive than their well-being counterparts in differentiating psychiatric and medical patients from healthy controls [22,23,30,34,35,37,40,42,50].

An opposite pattern was observed for the well-being subscales when discriminating among different subgroups of psychiatric and medical patients, or healthy subjects [22,37,42,50,55,62,80,111,122].

Cut-off scores

Various cut-off points have been suggested for the SQ scales and subscales [17], yet there has not been consensus about their positioning [22,53,69,70,72,78,79,81–86,90,100,103,104,129–137].

The SQ can be used as a screening tool for the identification of cases on the basis of normative parameters and cut-off points. However, it is not intended to be a diagnostic instrument. Rather, in the diagnostic process, a thorough clinical interview and assessment could include both self-report and observer-rated measures.

Sensitivity to change/responsiveness

Sensitivity to change has been assessed in numerous studies in which the SQ was used as a repeated rating outcome measure.

Pharmacological trials

In a variety of open studies, the SQ was able to show significant improvements in levels of psychological distress and well-being among patients with different psychiatric [27,32,37–39,59,61,63,100,138–153] and medical conditions [154,155], receiving psychotropic medications or other types of pharmacological treatments. In three of these studies [145,147,148], a pain subscale, based on the pain-related items of the SQ somatization scale, was used and showed to be sensitive to treatment changes.

In four studies [139,151,156,157], the SQ scales were sensitive to changes occurred at treatment interruption among patients with affective disorders who were taking psychotropic medications. In two studies [139,157], the SQ was also able to discriminate withdrawal symptoms that occurred after the interruption of selective serotonin reuptake inhibitors (SSRIs).

The ability of the SQ to discriminate drug effects has been evaluated in a number of placebo-controlled trials. Most of the SQ scales and subscales were highly sensitive in discriminating between effects of drugs and placebo among both psychiatric and medical patients [19,20,158–163]. Compared to placebo, drugs yielded significantly greater improvements in all studies.

In four negative placebo-controlled studies [100,137,164,165], significant improvements from baseline to the end of treatment were detected in SQ scores, without significant differences between drugs and placebo. The same results were obtained with observer-rated instruments [137,165].

Finally, the SQ was found to detect significant changes not only in treatment studies, but also after pharmacological challenges in patients with depression after tryptophan depletion [166] and fenfluramine challenge [167].

Psychotherapy studies

In a number of open trials, the SQ scores changed with psychological interventions in both clinical [26,29,64,168–171] and non-clinical populations [172–175].

The ability of the SQ to discriminate treatment effects has been evaluated in several controlled trials. In these trials, at least one of the SQ scales and subscales significantly discriminated between the effects of different psychological interventions [31,176–183]. Three of these studies were performed among middle and high school students receiving either a school-based protocol derived from well-being therapy (WBT) or attention placebo [181], anxiety management [182], and cognitive behavioral therapy (CBT) [180].

In other controlled studies, the SQ scales showed significant improvements from baseline to the end of psychological interventions, without significant differences between treatment groups [57,58,184–188].

Rehabilitation studies

In several investigations, levels of anxiety, depression, somatization, and hostility significantly decreased, according to the SQ scales and subscales, in different subgroups of patients undergoing cardiac or pulmonary rehabilitation [67–70,72,78,80–87,189–196], and among employees receiving a work-site health intervention [197]. In some of these studies, the SQ significantly discriminated between different degrees of improvement among subgroups of coronary artery disease patients [72,78,82,84,87,191,195].

Medical course and procedures

The SQ scores changed significantly among women undergoing amniocentesis [34,95,96,98], fetoscopy [97], or ultrasound examination [198]. In all of these studies, levels of distress and well-being significantly improved after the performance of the tests, with a further improvement when normal results were communicated.

In other longitudinal studies, the SQ scales and subscales were sensitive to changes in symptomatology observed among primipara women during the first 15 days post-partum [199], mothers of premature infants during the first 24 days of hospitalization in a neonatal intensive care unit [200], family caregivers of an elderly person at 2 weeks and 2 months after discharge from the hospital [201], and among medical patients at different evaluations over a period of time between 6 months and 5 years [66,91,92,103,202].

In four studies, the SQ scores significantly changed after the performance of a specific medical procedure, such as surgery or diagnostic testing [203–206].

Non-medical contexts

The SQ has also been administered in healthy populations. In the elderly a significant increase in levels of distress was detected after a major life crisis [110].

In other two studies [207,208], the SQ was administered to medical and dental students at different points during their programs. The SQ symptoms scores significantly increased over time starting from the beginning of the program. In one of these studies [207], medical students involved in a new, problem-based, and student-centered curriculum experienced significantly lower levels of psychological distress overall as compared to students in the traditional curriculum.

Symptoms versus well-being subscales

With the exception of three studies, in which at least one of the well-being subscales was more sensitive in discriminating between treatment effects [20,177,180], some or all of the symptoms subscales appeared to be more sensitive to treatment changes and differential effects than the corresponding well-being subscales, in both pharmacological and psychotherapy studies [29,37,61,80,142,143,155,159,179,181].

However, only the friendliness subscale was able to show significant improvements after treatment with amitriptyline in a subgroup of patients with major depressive disorder reporting losses [37].

Comparison with other scales

In eight studies [20,158–160,177,180–182], the SQ discriminated between the effects of drugs and placebo and those of different psychological interventions more sensitively than other self-rating scales, such as the SRT [18], the Beck Depression Inventory (BDI) [209], the Visual Analogue Scale (VAS) for pain [210], the Psychological Well-Being (PWB) scales [211], and the Revised Children's Manifest Anxiety Scale (RCMAS) [212]. In two of these studies [20,158], the SQ scales discriminated between the effects of psychotropic drugs and placebo more sensitively than observer-rating scales, including the Hamilton Anxiety Rating Scale [HARS] [213]. When a reduction in sample size was made by random methods to examine the sensitivity of the scales in a smaller sample [20], only the SQ and the SRT [18], but not the HARS [213], were still able to discriminate between chlordiazepoxide and placebo effects.

Only in two studies [214,215], the SQ was not able to discriminate between the effect of drug and placebo, showing lower sensitivity than the VAS for pain [210] and the Hamilton Rating Scale for Depression (HRSD) [216].

In four longitudinal studies [91,92,199,202], the SQ was more sensitive to symptoms changes than the HRSD [216] and the Clinical Interview for Depression (CID) [217,218], while in one study [66], the CID scales of anxiety and depression [217,218] showed greater sensitivity than the corresponding scales on the SQ.

Concurrent validity

The concurrent validity of the SQ has been examined with other self-rating scales measuring psychological distress. At least one of the SQ symptoms scales significantly and positively correlated with scales measuring similar constructs on the Profile of Mood States (POMS) [219], the Trauma Symptom Inventory [220], the SRT [18], the Hopkins Symptom Checklist (HSCL) [221], and the Center for Epidemiologic Studies-Depression Scale (CES-D) [222], in both clinical and non-clinical populations [17,34,46,199,223]. In these studies, correlation coefficients ranged from 0.39 to 0.93. Moreover, significant correlations were observed between the SQ hostility scale and the Perceived Stress Scale (PSS) [224] ($r = 0.46$) [27], the SQ contentment subscale and the CES-D [222] ($r = 0.48-0.53$) [34], and the SQ depression subscale and the SRT total neuroticism scale [18] ($r = 0.65-0.78$) [23], in depressed patients and controls.

Correlations between the SQ and self-rating scales of psychological well-being have also been evaluated in subjects from the general Italian population [126], and among psychiatric or medical patients and healthy controls [29,76]. Most of the PWB scales [211] significantly and negatively correlated with the SQ symptoms scores, and significantly and positively correlated with the well-being scores [29,76,126]. However, the degree of these correlations was highly variable for both symptoms ($r = 0.15-0.91$) and well-being ($r = 0.11-0.84$) subscales.

The relationship between the SQ and several observer-rated measures of distress has been investigated. Significant and positive correlations were observed between the HRSD [216], the HARS [213], the Montgomery-Åsberg Depression Rating Scale (MADRS) [225], the Brief Depression Rating Scale (BDRS) [226], and the CID [217,218], and at least one of the SQ symptoms scales among psychiatric or medical patients [17,22,27,34,38,63,124,129,136,202], and healthy subjects [34,37,38,128,129]. Specifically, correlation coefficients between the SQ depression score and the HRSD [216] ranged from 0.36 to 0.72 [34,124,128,129], and were slightly higher than those observed with the BDRS [226] ($r = 0.45-0.57$) [38] and the CID [217,218] ($r = 0.28-0.68$) [38,202]. Correlation coefficients between the SQ anxiety score and the HARS [213] ranged from 0.56 to 0.69 [17,128], and were higher than those observed with the CID anxiety scale [217,218] ($r = 0.35-0.54$) [202]. Moreover, in one investigation [34], the SQ contentment subscale significantly correlated with the HRSD [216] in both depressed patients ($r = 0.61$) and controls ($r = 0.54$). In three studies

[38,136,202], the correlation between the SQ and observer-rated measures increased with improvements of patients' clinical state and appeared to be higher when ratings did not reflect the severity of symptoms, but simply the presence or absence of symptoms.

Associations with other dimensions

Illness severity and quality of sleep

Significant and positive associations were observed between the SQ measures of distress and severity of disease in patients with medical [91,92,101,155,227] and psychiatric disorders [143].

In patients with chronic nightmare disorder receiving psychological interventions, the SQ scores of distress were significantly and inversely associated with nightmares decrease and quality of sleep [64,168,187].

Distress risk factors

In patients with cancer, SQ scores of depression were significantly and positively correlated with age [91,92] and days spent in isolation with fever during hospitalization [205].

In a sample of depressed patients treated with fluoxetine, post-treatment SQ scores of distress were significantly and inversely predicted by an earlier time to onset of clinical improvement (i.e., the first time point at which the HRSD score [216] decreased by at least 30% from baseline) [228] and baseline caffeine consumption [229], and significantly and positively predicted by baseline alcohol consumption and a greater number of medical comorbidities [230].

Finally, in a sample of patients with coronary artery disease, long-term statin use was significantly associated with a lower risk of developing symptoms of depression, anxiety, and hostility, according to the SQ scores [132].

Biomarkers

Only a few studies investigated the relationship between SQ scores of distress and biomarkers. Specifically, significant associations were found between SQ ratings of distress and changes in brain bioenergetics function among subjects with major depression [231], alterations in the white matter tract integrity among young adults exposed to childhood adversities [114,232], and the activation of specific areas in an extended neural network involved in facial expressions response, among healthy subjects with a genetic variation near the CREB1 [233].

In a sample of depressed outpatients [234], significant and positive correlations were found between the SQ score of anxiety and cardiovascular risk factors, such as levels of cholesterol and QTc interval.

In one study [110], changes in the SQ score of distress were significantly associated with physiological indicators of distress, such as blood levels of cortisol and the absorption of calories. In other two studies [88,161], the SQ depression and somatization scores were significantly associated with changes in levels of growth hormone among patients with prior acromegaly, with or without current growth hormone deficiency.

Traumatic experiences

Among young adults, exposure to various forms of maltreatment during childhood had a significant effect on SQ ratings of distress [128,235–238].

Moreover, intimate partner violence and coercion were significantly associated with higher levels of anxiety, depression, somatization, and hostility in samples of university students of different ethnicity [119,120,239–242].

Other psychological constructs

Several studies have shown the existence of a significant association between at least one of the SQ ratings of distress and well-being and a variety of other constructs, in both clinical and non-clinical settings. These constructs include measures of illness perception and hypochondriacal concerns [40,109,243–246]; alexithymia and emotional intelligence and regulation [183,203,247,248]; positive and negative cognitions [27,108]; anxiety sensitivity [156,249]; socio-affective vigilance [250]; perceptions of learning environment [207]; and different aspects of well-being, such as spiritual well-being, personal and social resourcefulness, coping abilities, perception of social support, and gratitude [93,108,251,252].

Among high school and undergraduate students (i.e., 13-23 years old), the SQ scores of distress were significantly associated with measures of illness behavior [253], perception of emotional intelligence [254], and hyperactivity/inattention [123].

Predictive validity

The predictive validity of the SQ has been examined in a number of studies with reference to its ability to predict a criterion measure at a later time.

Health outcomes

In patients affected by different medical conditions, higher SQ scores of distress significantly predicted worse health outcomes, such as greater disability, symptomatology, hospitalization, and use of medications [101,130,255,256].

In cardiology, patients who reported higher scores on the SQ distress scales had a significantly higher risk for adverse cardiac outcomes and mortality at 12- to 161-month follow-ups [69,70,72,79,80,86,133,257,258].

Moreover, worse SQ scores during pregnancy were significant risk factors for post-partum depression [135,259], early cessation of breastfeeding [134], and developmental or health problems in children at 3 years of follow-up [260,261].

Treatment outcomes

Among patients with affective disorders receiving psychotropic medication, higher SQ scores of anxiety and somatization at baseline significantly predicted worse treatment outcomes, such as reports of side effects [262], relapse [263], and poorer or delayed onset of clinical response (i.e. \geq 50% decrease in HRSD-17 [216] scores from baseline to endpoint) [125,264–266]. Similarly, early improvements in the anxiety, depression, and hostility scores significantly predicted response and remission (i.e. HAM-D-17 [216] score $<$ 8 at endpoint) after 8 weeks of treatment with fluoxetine in patients with major depressive disorder [149].

Among women with growth hormone deficiency [162] and patients with coronary artery disease [78,82,84,87], higher SQ scores of distress at baseline significantly predicted greater improvements in SQ scores of distress after growth hormone therapy or cardiac rehabilitation. A different trend was observed among oncological patients, where higher baseline SQ scores of depression and anxiety were significant predictors of the development of depression after autologous bone marrow transplantation [90].

Discussion

The SQ has been used in a variety of studies, in which it was administered to different populations of adolescents, adults, and elderly. Most of the SQ scales and subscales were able to discriminate between subgroups of subjects in both clinical and non-clinical settings, and to differentiate medical or psychiatric patients from healthy controls. In all studies in which the SQ was administered to psychiatric patients and healthy controls, most scales and subscales significantly discriminated between groups. The same scales showed to be highly sensitive to changes with pharmacological and psychotherapy interventions, and to significantly discriminate between treatment effects. In longitudinal studies, both symptoms and well-being scores changed over time in the expected direction. The present results have confirmed those summarized by Kellner in 1987 [17].

When compared with other self and observer-rated scales, a greater sensitivity of the SQ has emerged in its ability to discriminate between the effects of drugs and placebo, and the effects of different psychological interventions [20,158–160,177,180–182].

Compared to the well-being subscales, the SQ symptoms subscales showed greater discriminant validity in differentiating between patients and controls [22,23,30,34,35,37,40,42,50], and greater sensitivity to treatment changes and differential effects [29,37,61,80,142,143,155,159,179,181]. However, the well-being subscales were more sensitive to other differences between groups, such as those between subgroups of healthy subjects or between subgroups of patients affected by the same medical or psychiatric condition [22,37,42,50,55,62,80,111,122], and were able to show treatment changes in a specific subgroup of depressed patients, when other scales failed to do so [37]. Nevertheless, both subscales showed high sensitivity, being able to differentiate between remitted patients and healthy controls [24,29,30,40,41].

In line with data reported in Kellner [17], significant correlations were found between the SQ and other self- and observer-rating scales. In psychometrics, a high correlation is often regarded as evidence that two scales measure the same factor. However, high correlations do not necessarily indicate similar sensitivity [10,20], as illustrated in several of the studies examined in the present review [20,37,38,46,108,199,202]. High, statistically significant correlations are due to the presence of common contents among scales measuring similar constructs, but the items and properties that these scales do not share determine their sensitivity [10,20,267,268]. The use of both observer and self-rated scales has been recommended to yield information that might not be revealed if only one scale is used [129].

As outlined in several studies in the present review, the SQ scores have shown a significant prognostic value, being associated with a variety of medical outcomes and biological or psychological variables. Therefore, the assessment of both levels of well-being and distress contributes not only to a more complete evaluation of the patient's health status, but also to the development of more effective and personalized interventions. Moreover, due to its extreme sensitivity, the SQ appears to be useful in studies with small or moderate sample sizes, in which the sensitivity of the scale is important, and in psychiatric and psychosomatic investigations, where specific changes in the patient's psychological condition are investigated.

The SQ, compared to other similar PROs, carries a number of advantages. First, it has brief items instead of questions and yes/no and true/false responses instead of scales of severity or frequency of symptoms. For its brevity and simplicity, it is thus particularly suitable for populations of subjects with limited verbal skills and can be used in busy clinical practice or as an epidemiological screening procedure to differentiate moderate and severe distress or for other clinical routines, such as the

assessment of treatment effects and the psychological reactions to medical procedures. Even though it is generally assumed that graded response scales provide maximum sensitivity, these may be more confusing for many patients than simple judgments of items as present or absent [269]. The sensitivity of the SQ may be related to the fact that patients are required to make a simple yes/no judgment about the presence of each symptom, with less opportunities for subjects to amplify or minimize symptoms to make distinction about qualities, degrees, and patterns of distress [269].

Second, there are many self-report inventories that have been developed that are geared to the assessment of one specific dimension, often subsumed under the rubric of depression or anxiety [268,270]. The SQ provides simultaneous assessment of both symptom and well-being dimensions. The four symptom dimensions (anxiety, depression, hostility, and somatization) are key elements of a subject's clinical state. The subscale of hostility captures an affective component that is often neglected in diagnostic interviewing and this is subsumed under the rubric of irritable mood, i.e., a feeling state characterized by irritability which requires an increased effort of control over temper or results in irascible verbal and behavioral outbursts [6]. There are other multidimensional scales that are available and have been found to be sensitive in clinical trials, such as the HSCL [221,269]. However, they lack the psychological well-being dimensions that may provide important information in specific clinical settings, such as with subclinical symptomatology and/or impaired psychological well-being.

The findings of this review thus indicate that the SQ fulfills the criteria for a comprehensive and highly sensitive clinimetric index and represents one of the most sensitive patient-reported outcome measure (PRO) available, if not the most sensitive. It may provide clinical information that other similar scales fail to provide and that may supplement the data derived from interview methods. It can be used with adult subjects, as well as with adolescents and in older individuals. Its use is recommended in clinical investigations concerned with psychiatric patients, with particular reference to drug trials [7], psychotherapy studies [271], and network analyses of psychopathology [272]. Because of its sensitivity, the SQ may be particularly suitable for detecting psychological distress or impairment in well-being in populations characterized by subclinical or mild symptoms [38]. In medical settings, it may disclose distress and impaired quality of life associated with disorders [6], iatrogenic psychopathology [273], and be a screening method to assess psychosocial problems [103,274,275]. The joint assessment of well-being and distress is in line with current emphasis on psychological well-being and the evolving science of euthymia [5]. Robert Kellner should be credited for developing in the seventies a clinimetric tool that was far ahead of its time and that is more timely than ever.

Disclosure Statement

All authors have no conflicts of interest to declare

Funding sources

None.

Author Contributions

All Authors conceived the project G. Benasi and C. Rafanelli performed the searches and collected the data. All authors analyzed the data. All authors drafted and revised the manuscript.

References

1. Basch E. Patient-reported outcomes - harnessing patients' voices to improve clinical care. *N Engl J Med*. 2017 Jan;376(2):105–8.
2. Fava GA, Tomba E, Brakemeier EL, Carrozzino D, Cosci F, Eöry A, et al. Mental pain as a transdiagnostic patient-reported outcome measure. *Psychother Psychosom*. 2019;88(6):341–9.
3. Bech P, Timmerby N. An overview of which health domains to consider and when to apply them in measurement-based care for depression and anxiety disorders. *Nord J Psychiatry*. 2018 Jul;72(5):367–73.
4. Carrozzino D, Svicher A, Patierno C, Berrocal C, Cosci F. The euthymia scale: a clinimetric analysis. *Psychother Psychosom*. 2019;88(2):119–21.
5. Fava GA, Guidi J. The pursuit of euthymia. *World Psychiatry*. 2020; 19 (1):40-50
6. Fava GA, Cosci F, Sonino N. Current psychosomatic practice. *Psychother Psychosom*. 2017;86(1):13–30.
7. Fava GA, Tomba E, Bech P. Clinical pharmacopsychology: conceptual foundations and emerging tasks. *Psychother Psychosom*. 2017;86(3):134–40.
8. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols. *JAMA*. 2018 Feb;319(5):483.
9. Bech P. Modern psychometrics in clinimetrics: impact on clinical trials of antidepressants. *Psychother Psychosom*. 2004 May-Jun;73(3):134–8.
10. Fava GA, Ruini C, Rafanelli C. Psychometric theory is an obstacle to the progress of clinical research. *Psychother Psychosom*. 2004 May-Jun;73(3):145–8.
11. Kellner R. Improvement criteria in drug trials with neurotic patients. Part 2. *Psychol Med*. 1972 Feb;2(1):73–80.
12. Feinstein AR. T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. *Circulation*. 1982 Jul;66(1):1–5.
13. Feinstein AR. *Clinimetrics*. New Haven, CT, Yale University Press, 1987.
14. Fava GA, Tomba E, Sonino N. Clinimetrics: the science of clinical measurements. *Int J Clin Pract*. 2012 Jan;66(1):11–5.
15. Fava GA, Carrozzino D, Lindberg L, Tomba E. The clinimetric approach to psychological assessment: A Tribute to Per Bech, MD (1942-2018). *Psychother Psychosom*.

2018;87(6):321–6.

16. Kellner R. Abridged manual of the Symptom Questionnaire. Albuquerque: University of New Mexico; 1976.
17. Kellner R. A Symptom Questionnaire. *J Clin Psychiatry*. 1987 Jul;48(7):268–74.
18. Kellner R, Sheffield BF. A self-rating scale of distress. *Psychol Med*. 1973 Feb;3(1):88–100.
19. Kellner R, Bruzzese D, Winslow WW, Rada RT, Wall FJ. The effects of one- day treatment of anxiety with high doses of halazepam. *J Clin Pharmacol*. 1978 Apr;18(4):203–9.
20. Kellner R, Rada RT, Andersen T, Pathak D. The effects of chlordiazepoxide on self-rated depression, anxiety, and well-being. *Psychopharmacology (Berl)*. 1979 Aug;64(2):185–91.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009 Jul;6(7):e1000097.
22. Fava GA, Kellner R, Munari F, Pavan L, Pesarin F. Losses, hostility, and depression. *J Nerv Ment Dis*. 1982 Aug;170(8):474–8.
23. Fava GA. Neurotic symptoms and major depressive illness. *Psychiatr Clin (Basel)*. 1982;15(4):231–8.
24. Molnar G, Fava GA, Zielezny M, Spinks MT, Loretan A. Measurement of subclinical changes during lithium prophylaxis: a longitudinal study. *Psychopathology*. 1987;20(3–4):155–61.
25. Kellner R, Abbott P, Winslow WW, Pathak D. Anxiety, depression, and somatization in DSM-III hypochondriasis. *Psychosomatics*. 1989;30(1):57–64.
26. Fava GA, Grandi S, Rafanelli C, Saviotti FM, Ballin M, Pesarin F. Hostility and irritable mood in panic disorder with agoraphobia. *J Affect Disord*. 1993 Dec;29(4):213–7.
27. Fava M, Davidson K, Alpert JE, Nierenberg AA, Worthington J, O’Sullivan R, et al. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. *J Psychiatr Res*. 1996;30(6):459–67.
28. Zeffert S, Clark A, Dobson CJ, Jones A, Peck D. The symptom questionnaire: British standardization data. *Br J Clin Psychol*. 1996 Feb;35(1):85–90.
29. Rafanelli C, Park SK, Ruini C, Ottolini F, Cazzaro M, Fava GA. Rating well-being and distress. *Stress Med*. 2000;16(1):55–61.
30. Fava GA, Rafanelli C, Ottolini F, Ruini C, Cazzaro M, Grandi S. Psychological well-being

and residual symptoms in remitted patients with panic disorder and agoraphobia. *J Affect Disord.* 2001 Jul;65(2):185–90.

31. Grandi S, Fabbri S, Panattoni N, Gonnella E, Marks I. Self-exposure treatment of recurrent nightmares: waiting-list-controlled trial and 4-year follow-up. *Psychother Psychosom.* 2006;75(6):384–8.
32. López-Solà M, Pujol J, Hernández-Ribas R, Harrison BJ, Contreras-Rodríguez O, Soriano-Mas C, et al. Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder. *Neuropsychopharmacology.* 2010 Oct;35(11):2305–17.
33. Grandi S, Clementi C, Guidi J, Benassi M, Tossani E. Personality characteristics and psychological distress associated with primary exercise dependence: an exploratory study. *Psychiatry Res.* 2011 Sep;189(2):270–5.
34. Fava GA, Kellner R, Perini GI, Fava M, Michelacci L, Munari F, et al. Italian validation of the Symptom Rating Test (SRT) and Symptom Questionnaire (SQ). *Can J Psychiatry.* 1983 Mar;28(2):117–23.
35. Kellner R, Abbott P, Pathak D, Winslow WW, Umland BE. Hypochondriacal beliefs and attitudes in family practice and psychiatric patients. *Int J Psychiatry Med.* 1983-1984;13(2):127–39.
36. Fava GA, Molnar G, Spinks M, Loretan A, Bartlett D. Health attitudes and psychological distress in patients attending a lithium clinic. *Acta Psychiatr Scand.* 1984 Dec;70(6):591–3.
37. Fava GA, Kellner R, Lisansky J, Park S, Perini GI, Zielesny M. Hostility and recovery from melancholia. *J Nerv Ment Dis.* 1986 Jul;174(7):414–7.
38. Fava GA, Kellner R, Lisansky J, Park S, Perini GI, Zielesny M. Rating depression in normals and depressives: observer versus self-rating scales. *J Affect Disord.* 1986 Jul-Aug;11(1):29–33.
39. Kellner R, Fava GA, Lisansky J, Perini GI, Zielesny M. Hypochondriacal fears and beliefs in DSM-III melancholia. Changes with amitriptyline. *J Affect Disord.* 1986 Jan-Feb;10(1):21–6.
40. Fava GA, Molnar G, Zielesny M. Health attitudes of psychiatric inpatients. *Psychopathology.* 1987;20(3–4):180–6.
41. Fava GA, Molnar G, Zielesny M, Loretan A, Spinks MT. Hostility and irritable mood during lithium prophylaxis: a longitudinal study. *Med Sci Res.* 1987;15:901–2.
42. Ruini C, Vescovelli F, Albieri E. Post-traumatic growth in breast cancer survivors: new

insights into its relationships with well-being and distress. *J Clin Psychol Med Settings*. 2013 Sep;20(3):383–91.

43. Fava GA, Fava M, Kellner R, Serafini E, Mastrogiacomo I. Depression, hostility and anxiety in hyperprolactinemic amenorrhea. *Psychother Psychosom*. 1981;36(2):122–8.
44. Fava M, Fava GA, Kellner R, Serafini E, Masirogiacomo I. Psychological correlates of hyperprolactinemia in males. *Psychother Psychosom*. 1982;37(4):214–7.
45. Mastrogiacomo I, Fava M, Fava GA, Kellner R, Grismondi G, Cetera C. Postpartum hostility and prolactin. *Int J Psychiatry Med*. 1982-1983;12(4):289–94.
46. Mastrogiacomo I, Fava M, Fava GA, Serafini E, De Besi L. Correlations between psychological symptoms in hyperprolactinemic amenorrhea. *Neuroendocrinol Lett*. 1983;5(2):117–22.
47. Kellner R, Buckman MT, Fava GA, Pathak D. Hyperprolactinemia, distress, and hostility. *Am J Psychiatry*. 1984 Jun;141(6):759–63.
48. Fava M, Serafini E, De Besi L, Adami A, Mastrogiacomo I. Hyperprolactinemia and psychological distress in women undergoing chronic hemodialysis. *Psychother Psychosom*. 1988;49(1):6–9.
49. Fava GA, Grandi S, Savron G, Bartolucci G, Santarsiero G, Trombini G, et al. Psychosomatic assessment of hirsute women. *Psychother Psychosom*. 1989;51(2):96–100.
50. Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. Psychological assessment of primary aldosteronism: a controlled study. *J Clin Endocrinol Metab*. 2011 Jun;96(6):E878–83.
51. Chattat R, Bazzocchi G, Balloni M, Conti E, Ercolani M, Zaccaroni S, et al. Illness behavior, affective disturbance and intestinal transit time in idiopathic constipation. *J Psychosom Res*. 1997 Jan;42(1):95–100.
52. Golfieri L, Lauro A, Tossani E, Sirri L, Venturoli A, Dazzi A, et al. Psychological adaptation and quality of life of adult intestinal transplant recipients: University of Bologna experience. *Transplant Proc*. 2010 Jan-Feb;42(1):42–4.
53. Carrozzino D, Marchetti D, Laino D, Minna M, Verrocchio MC, Fulcheri M, et al. Anxiety in adolescent epilepsy. A clinimetric analysis. *Nord J Psychiatry*. 2016 Aug;70(6):424–9.
54. Guidi J, Gambineri A, Zanutti L, Fanelli F, Fava GA, Pasquali R. Psychological aspects of hyperandrogenic states in late adolescent and young women. *Clin Endocrinol (Oxf)*. 2015

Dec;83(6):872–8.

55. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of depressed patients with comorbid diabetes mellitus. *Int Clin Psychopharmacol*. 2006 Jan;21(1):43–7.
56. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. *Arch Pediatr Adolesc Med*. 2007 Jan;161(1):22–9.
57. Monti F, Tonetti L, Bitti PE. Effectiveness of psychological treatments delivered at a counseling service for students. *Psychol Rep*. 2013 Dec;113(3):955–68.
58. Monti F, Tonetti L, Ricci Bitti PE. Short-term effectiveness of psychotherapy treatments delivered at a university counselling service. *Br J Guid Couns*. 2016;44(4):414–22.
59. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, Part 1: clinical correlates and response to fluoxetine treatment. *Am J Psychiatry*. 1993 Aug;150(8):1158–63.
60. Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Fava M, Renshaw PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. *Biol Psychiatry*. 1997 Jul;42(2):79–84.
61. Mischoulon D, Dougherty DD, Bottonari KA, Gresham RL, Sonawalla SB, Fischman AJ, et al. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. *Psychiatry Res*. 2002 Dec;116(3):151–61.
62. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, et al. Obesity among outpatients with major depressive disorder. *Int J Neuropsychopharmacol*. 2005 Mar;8(1):59–63.
63. Denninger JW, Papakostas GI, Mahal Y, Merens W, Alpert JE, Nierenberg AA, et al. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. *Psychosomatics*. 2006 Jul-Aug;47(4):348–52.
64. Krakow B, Johnston L, Melendrez D, Hollifield M, Warner TD, Chavez-Kennedy D, et al. An open-label trial of evidence-based cognitive behavior therapy for nightmares and insomnia in crime victims with PTSD. *Am J Psychiatry*. 2001 Dec;158(12):2043–7.

65. Krakow B, Haynes PL, Warner TD, Melendrez D, Sisley BN, Johnston L, et al. Clinical sleep disorder profiles in a large sample of trauma survivors: an interdisciplinary view of posttraumatic sleep disturbance. *Sleep Hypn.* 2007;9(1):6–15.
66. Fava GA, Magelli C, Savron G, Conti S, Bartolucci G, Grandi S, et al. Neurocirculatory asthenia: a reassessment using modern psychosomatic criteria. *Acta Psychiatr Scand.* 1994 May;89(5):314–9.
67. Milani RV, Lavie CJ. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. *Am J Med.* 1996 May;100(5):517–23.
68. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO. The obesity paradox, weight loss, and coronary disease. *Am J Med.* 2009 Dec;122(12):1106–14.
69. Milani RV, Lavie CJ. Reducing psychosocial stress: a novel mechanism of improving survival from exercise training. *Am J Med.* 2009 Oct;122(10):931–8.
70. De Schutter A, Lavie CJ, Milani RV. Relative importance of comorbid psychological symptoms in patients with depressive symptoms following phase II cardiac rehabilitation. *Postgrad Med.* 2011 Nov;123(6):72–8.
71. Grandi S, Sirri L, Tossani E, Fava GA. Psychological characterization of demoralization in the setting of heart transplantation. *J Clin Psychiatry.* 2011 May;72(5):648–54.
72. Milani RV, Lavie CJ, Mehra MR, Ventura HO. Impact of exercise training and depression on survival in heart failure due to coronary heart disease. *Am J Cardiol.* 2011 Jan;107(1):64–8.
73. Rafanelli C, Offidani E, Gostoli S, Roncuzzi R. Psychological correlates in patients with different levels of hypertension. *Psychiatry Res.* 2012 Jun;198(1):154–60.
74. Guidi J, Rafanelli C, Roncuzzi R, Sirri L, Fava GA. Assessing psychological factors affecting medical conditions: comparison between different proposals. *Gen Hosp Psychiatry.* 2013 Mar-Apr;35(2):141–6.
75. Rafanelli C, Gostoli S, Roncuzzi R, Sassone B. Psychological correlates of vasovagal versus medically unexplained syncope. *Gen Hosp Psychiatry.* 2013 May-Jun;35(3):246–52.
76. Gostoli S, Rafanelli C, Offidani E, Marchetti G, Roncuzzi R, Urbinati S. Well-being, ill-being and symptoms of atrial fibrillation. *J Cardiovasc Med.* 2014 Mar;15(3):260–2.
77. Guidi J, Offidani E, Rafanelli C, Roncuzzi R, Sonino N, Fava GA. The assessment of allostatic overload in patients with congestive heart failure by clinimetric criteria. *Stress Heal.* 2016 Feb;32(1):63–9.

78. Milani RV, Lavie CJ, Cassidy MM. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. *Am Heart J*. 1996 Oct;132(4):726–32.
79. Kachur S, Menezes AR, De Schutter A, Milani RV, Lavie CJ. Significance of comorbid psychological stress and depression on outcomes after cardiac rehabilitation. *Am J Med*. 2016 Dec;129(12):1316–21.
80. Gostoli S, Roncuzzi R, Urbinati S, Rafanelli C. Clinical and subclinical distress, quality of life, and psychological well-being after cardiac rehabilitation. *Appl Psychol Heal Well-Being*. 2017 Nov;9(3):349–69.
81. Milani RV, Lavie CJ. Prevalence and effects of cardiac rehabilitation on depression in the elderly with coronary heart disease. *Am J Cardiol*. 1998 May;81(10):1233–6.
82. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs on coronary patients with high levels of hostility. *Mayo Clin Proc*. 1999 Oct;74(10):959–66.
83. Lavie CJ, Milani RV, Cassidy MM, Gilliland YE. Effects of cardiac rehabilitation and exercise training programs in women with depression. *Am J Cardiol*. 1999 May;83(10):1480–3.
84. Lavie CJ, Milani RV. Prevalence of anxiety in coronary patients with improvement following cardiac rehabilitation and exercise training. *Am J Cardiol*. 2004 Feb;93(3):336–9.
85. Lavie CJ, Milani RV. Prevalence of hostility in young coronary artery disease patients and effects of cardiac rehabilitation and exercise training. *Mayo Clin Proc*. 2005 Mar;80(3):335–42.
86. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. *Am J Med*. 2007 Sep;120(9):799–806.
87. Artham SM, Lavie CJ, Milani RV. Cardiac rehabilitation programs markedly improve high-risk profiles in coronary patients with high psychological distress. *South Med J*. 2008 Mar;101(3):262–7.
88. Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. *J Clin Endocrinol Metab*. 2009 Jul;94(7):2471–7.
89. Robinson JK, Boshier ML, Dansak DA, Peterson KJ. Depression and anxiety in cancer patients: evidence for different causes. *J Psychosom Res*. 1985;29(2):133–8.
90. Grassi L, Rosti G, Albertazzi L, Marangolo M. Depressive symptoms in autologous bone

marrow transplant (ABMT) patients with cancer: an exploratory study. *Psychooncology*. 1996;5(4):305–10.

91. Giusti M, Sibilla F, Cappi C, Dellepiane M, Tombesi F, Ceresola E, et al. A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. *J Endocrinol Invest*. 2005 Jul-Aug;28(7):599–608.
92. Giusti M, Melle G, Fenocchio M, Mortara L, Cecoli F, Caorsi V, et al. Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. *J Zhejiang Univ Sci B*. 2011 Mar;12(3):163–73.
93. Ruini C, Vescovelli F. The role of gratitude in breast cancer: its relationships with post-traumatic growth, psychological well-being and distress. *J Happiness Stud*. 2013;14(1):263–74.
94. Offidani E, Del Basso D, Prignano F, Tomba E. Discriminating the presence of psychological distress in patients suffering from psoriasis: an application of the clinimetric approach in dermatology. *Acta Derm Venereol*. 2016 Aug;96(217):69–73.
95. Fava GA, Kellner R, Michelacci L, Trombini G, Pathak D, Orlandi C. Psychological reactions to amniocentesis: a controlled study. *Am J Obstet Gynecol*. 1982 Jul;143(5):509–13.
96. Fava GA, Trombini G, Michelacci L, Linder JR, Pathak D, Bovicelli L. Hostility in women before and after amniocentesis. *J Reprod Med Obstet Gynecol*. 1983 Jan;28(1):29–34.
97. Fava GA, Michelacci L, Trombini G, Bovicelli L, Orlandi C. Psychological reactions to fetoscopy: a controlled study. *Prenat Diagn*. 1984 Nov-Dec;4(6):397–404.
98. Michelacci L, Fava GA, Trombini G, Zielezny M, Bovicelli L, Orlandi C. Psychological distress and amniocentesis. *Gynecol Obstet Invest*. 1984;18(1):40–4.
99. Slocumb JC, Kellner R, Rosenfeld RC, Pathak D. Anxiety and depression in patients with the abdominal pelvic pain syndrome. *Gen Hosp Psychiatry*. 1989 Jan;11(1):48–53.
100. Cerutti R, Sichel MP, Perin M, Grussu P, Zulian O. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. *Curr Ther Res*. 1993 Jun;53(6):707–16.
101. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic respiratory impairment. *Gen Hosp Psychiatry*. 1992 Jan;14(1):20–8.
102. Hashimoto F, Kellner R, Kapsner CO. Upper respiratory tract infections increase self-rated hostility and distress. *Int J Psychiatry Med*. 1987;17(1):41–7.

103. Ceroni GB, Ceroni FB, Bivi R, Corsino MA, De Marco P, Gallo E, et al. DSM-III mental disorders in general medical sector: a follow-up and incidence study over a two-year period. *Soc Psychiatry Psychiatr Epidemiol.* 1992;27(5):234–41.
104. Hollifield M, Tuttle L, Paine S, Kellner R. Hypochondriasis and somatization related to personality and attitudes toward self. *Psychosomatics.* 1999 Sep-Oct;40(5):387–95.
105. McGettigan MC, Greenspan JS, Antunes MJ, Greenspan DI, Rubenstein SD. Psychological aspects of parenting critically ill neonates. *Clin Pediatr (Phila).* 1994 Feb;33(2):77–82.
106. Avasthi A, Grover S, Kaur R, Prakash O, Kulhara P. Impact of nonorganic erectile dysfunction on spouses: a study from India. *J Sex Med.* 2010 Nov;7(11):3666–74.
107. Arévalo-Flechas LC, Acton G, Escamilla MI, Bonner PN, Lewis SL. Latino Alzheimer's caregivers: What is important to them? *J Manag Psychol.* 2014;29(6):661–84.
108. Bekhet AK. Resourcefulness in African American and Caucasian American caregivers of persons with dementia: associations with perceived burden, depression, anxiety, positive cognitions, and psychological well-being. *Perspect Psychiatr Care.* 2015 Oct;51(4):285–94.
109. Kellner R, Pathak D, Romanik R, Winslow WW. Life events and hypochondriacal concerns. *Psychiatr Med.* 1983 Jun;1(2):133–41.
110. Willis L, Thomas P, Garry PJ, Goodwin JS. A prospective study of response to stressful life events in initially healthy elders. *Journals Gerontol.* 1987 Nov;42(6):627–30.
111. Tomoda A, Suzuki H, Rabi K, Sheu YS, Polcari A, Teicher MH. Reduced prefrontal cortical gray matter volume in young adults exposed to harsh corporal punishment. *Neuroimage.* 2009 Aug;47(Suppl. 2):T66–71.
112. Sheu YS, Polcari A, Anderson CM, Teicher MH. Harsh corporal punishment is associated with increased T2 relaxation time in dopamine-rich regions. *Neuroimage.* 2010 Nov;53(2):412–9.
113. Tomoda A, Sheu YS, Rabi K, Suzuki H, Navalta CP, Polcari A, et al. Exposure to parental verbal abuse is associated with increased gray matter volume in superior temporal gyrus. *Neuroimage.* 2011 Jan;54(Suppl. 1):S280–6.
114. Choi J, Jeong B, Polcari A, Rohan ML, Teicher MH. Reduced fractional anisotropy in the visual limbic pathway of young adults witnessing domestic violence in childhood. *Neuroimage.* 2012 Jan;59(2):1071–9.
115. Tomoda A, Polcari A, Anderson CM, Teicher MH. Reduced visual cortex gray matter volume and thickness in young adults who witnessed domestic violence during childhood. *PLoS One.*

2012;7(12):e52528.

116. Pechtel P, Lyons-Ruth K, Anderson CM, Teicher MH. Sensitive periods of amygdala development: the role of maltreatment in preadolescence. *Neuroimage*. 2014 Aug;97:236–44.
117. Teicher MH, Anderson CM, Ohashi K, Polcari A. Childhood maltreatment: altered network centrality of cingulate, precuneus, temporal pole and insula. *Biol Psychiatry*. 2014 Aug;76(4):297–305.
118. Teicher MH, Ohashi K, Khan A, Garcia LCH, Klengel T, Anderson CM, et al. Does sleep disruption mediate the effects of childhood maltreatment on brain structure? *Eur J Psychotraumatol*. 2017;8(Suppl. 7):1450594.
119. Próspero M. Mental health symptoms among male victims of partner violence. *Am J Mens Health*. 2007 Dec;1(4):269–77.
120. Prospero M, Kim M. Ethnic difference in the effects of coercion on mental health and the use of therapy. *J Soc Work Pract*. 2009 Mar;23(1):77–91.
121. Amianto F, Daga GA, Bertorello A, Fassino S. Exploring personality clusters among parents of ED subjects. Relationship with parents' psychopathology, attachment, and family dynamics. *Compr Psychiatry*. 2013 Oct;54(7):797–811.
122. Kellner R, Wiggins RJ, Pathak D. Distress in medical and law students. *Compr Psychiatry*. 1986;27(3):220–3.
123. Vescovelli F, Albieri E, Ruini C. Self-rated and observer-rated measures of well-being and distress in adolescence: an exploratory study. *Springerplus*. 2014;3(1):490.
124. Fava M, Nolan S, Kradin R, Rosenbaum J. Gender differences in hostility among depressed and medical outpatients. *J Nerv Ment Dis*. 1995 Jan;183(1):10–4.
125. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, et al. Somatic symptoms in treatment-resistant depression. *Psychiatry Res*. 2003 May;118(1):39–45.
126. Ruini C, Ottolini F, Rafanelli C, Tossani E, Ryff CD, Fava GA. The relationship of psychological well-being to distress and personality. *Psychother Psychosom*. 2003;72(5):268–75.
127. Rai RN, Pandey RC, Kumar K. Perceived parental rearing style and personality among Khasi adolescents. *J Indian Acad Appl Psychol*. 2009;35(Special Issue):57–60.
128. Polcari A, Rabi K, Bolger E, Teicher MH. Parental verbal affection and verbal aggression in childhood differentially influence psychiatric symptoms and wellbeing in young adulthood.

Child Abus Negl. 2014 Jan;38(1):91–102.

129. Fava GA, Kellner R, Munari F, Pavan L. The Hamilton Depression Rating Scale in normals and depressives. *Acta Psychiatr Scand*. 1982 Jul;66(1):26–32.
130. Hollifield M, Paine S, Tuttle L, Kellner R. Hypochondriasis, somatization, and perceived health and utilization of health care services. *Psychosomatics*. 1999 Sep-Oct;40(5):380–6.
131. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J*. 2003 Aug;14(3):164–8.
132. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. Long-term statin use and psychological well-being. *J Am Coll Cardiol*. 2003 Aug;42(4):690–7.
133. Shibeshi WA, Young-Xu Y, Blatt CM. Anxiety worsens prognosis in patients with coronary artery disease. *J Am Coll Cardiol*. 2007 May;49(20):2021–7.
134. Kehler HL, Chaput KH, Tough SC. Risk factors for cessation of breastfeeding prior to six months postpartum among a community sample of women in Calgary, Alberta. *Can J Public Heal*. 2009;100(5):376–80.
135. Davey HL, Tough SC, Adair CE, Benzies KM. Risk factors for sub-clinical and major postpartum depression among a community cohort of canadian women. *Matern Child Health J*. 2011 Oct;15(7):866–75.
136. Fisher LB, Fava M, Doros GD, Alpert JE, Henry M, Huz I, et al. The role of anger/hostility in treatment-resistant depression: a secondary analysis from the ADAPT-A Study. *J Nerv Ment Dis*. 2015 Oct;203(10):762–8.
137. Ionescu DF, Fava M, Kim DJ, Baer L, Shelton RC, Cusin C. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. *Ther Adv Psychopharmacol*. 2016 Feb;6(1):4–12.
138. Cohen LS, Viguera AC, Bouffard SM, Nonacs RM, Morabito C, Collins MH, et al. Venlafaxine in the treatment of postpartum depression. *J Clin Psychiatry*. 2001 Aug;62(8):592–6.
139. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. *J Clin Psychiatry*. 2001 Jun;62(6):413–20.
140. Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, et al.

Fluoxetine treatment of depressed patients with comorbid anxiety disorders. *J Psychopharmacol*. 2002 Sep;16(3):215–9.

141. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, et al. S-adenosyl-L-methionine (SAME) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. *J Clin Psychopharmacol*. 2004 Dec;24(6):661–4.
142. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. *J Clin Psychiatry*. 2004 Feb;65(2):217–21.
143. Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. *Psychiatr Q*. 2004;75(4):309–20.
144. Nonacs RM, Soares CN, Viguera AC, Pearson K, Poitras JR, Cohen LS. Bupropion SR for the treatment of postpartum depression: a pilot study. *Int J Neuropsychopharmacol*. 2005 Sep;8(3):445–9.
145. Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG, Detke MJ. Duloxetine in the treatment of major depressive disorder: an open-label study. *BMC Psychiatry*. 2007;7:43.
146. Perahia DG, Quail D, Desai D, Corruble E, Fava M. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. *J Clin Psychiatry*. 2008 Jan;69(1):95–105.
147. Irene R, Luis MA, Helena DC, David P, Ramon DJ, Inmaculada G. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: results from a Spanish sample. *Int J Psychiatry Clin Pract*. 2009;13(2):100–8.
148. Perahia DG, Quail D, Desai D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. *J Psychiatr Res*. 2009 Feb;43(5):512–8.
149. Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, et al. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. *Ann Clin Psychiatry*. 2010 Aug;22(3):166–71.
150. Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. *Brain Behav*. 2016 Jul;6(10):e00520.

151. Fava M, Mard F, Davidsen CK, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. *J Clin Psychiatry*. 2016 Dec;77(12):1695–701.
152. Weisler RH, Ota A, Tsuneyoshi K, Perry P, Weiller E, Baker RA, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. *J Affect Disord*. 2016 Nov;204:40–7.
153. Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. *J Clin Psychiatry*. 1999 Sep;60(9):580–3.
154. Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M. Slow-release lanreotide treatment in acromegaly: effects on quality of life. *Psychother Psychosom*. 1999;68(3):165–7.
155. Walker SE, Smarr KL, Parker JC, Weidensaul DN, Nelson W, McMurray RW. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine. *Lupus*. 2000;9(7):527–33.
156. Fava GA, Grandi S, Belluardo P, Savron G, Raffi AR, Conti S, et al. Benzodiazepines and anxiety sensitivity in panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 1994 Nov;18(7):1163–8.
157. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. *Biol Psychiatry*. 1998 Jul;44(2):77–87.
158. Kellner R, Collins AC, Shulman RS, Pathak D. The short- term antianxiety effects of propranolol HCL. *J Clin Pharmacol*. 1974 May-Jun;14(5–6):301–4.
159. Buckman MT, Kellner R. Reduction of distress in hyperprolactinemia with bromocriptine. *Am J Psychiatry*. 1985 Feb;142(2):242–4.
160. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. *Br J Psychiatry*. 2006 Apr;188:346–53.
161. Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. *J Clin Endocrinol Metab*. 2010 Feb;95(2):567–77.
162. Valassi E, Brick DJ, Johnson JC, Biller BM, Klibanski A, Miller KK. Effect of growth

hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders. *Endocr Pract.* 2012 Mar-Apr;18(2):209–18.

163. Dording C, Cassiello C, King F 4th, Pencina M, Fava M, Mischoulon D. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. *Int Clin Psychopharmacol.* 2013 Sep;28(5):238–44.
164. Magelli C, Fava GA, Grandi S, Semprini F, Bassein L, Capelletti D, et al. Illness attitudes of patients suffering from mild heart failure during a pharmacological trial. *Med Sci Res.* 1988;16:239–40.
165. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, et al. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. *J Clin Psychiatry .* 2012 Mar;73(3):353–7.
166. Spillmann MK, Van der Does AJ, Rankin MA, Vuolo RD, Alpert JE, Nierenberg AA, et al. Tryptophan depletion in SSRI-recovered depressed outpatients. *Psychopharmacology (Berl).* 2001 May;155(2):123–7.
167. Fava M, Vuolo RD, Wright EC, Nierenberg AA, Alpert JE, Rosenbaum JF. Fenfluramine challenge in unipolar depression with and without anger attacks. *Psychiatry Res.* 2000 Apr;94(1):9–18.
168. Krakow B, Kellner R, Pathak D, Lambert L. Long term reduction of nightmares with imagery rehearsal treatment. *Behav Cogn Psychother.* 1996;24(2):135–48.
169. Krakow BJ, Melendrez DC, Johnston LG, Clark JO, Santana EM, Warner TD, et al. Sleep dynamic therapy for Cerro Grande fire evacuees with posttraumatic stress symptoms: a preliminary report. *J Clin Psychiatry.* 2002 Aug;63(8):673–84.
170. Farabaugh A, Locascio JJ, Yap L, Growdon J, Fava M, Crawford C, et al. Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. *Psychosomatics.* 2010 Mar-Apr;51(2):124–9.
171. Ruini C, Masoni L, Ottolini F, Ferrari S. Positive narrative group psychotherapy: the use of traditional fairy tales to enhance psychological well-being and growth. *Psychol Well Being.* 2014;4(1):13.
172. Fava M, Litman A, Halperin P, Prater E, Drews FR, Oleshansky M, et al. Psychological and

behavioral benefits of a stress/type A behavior reduction program for healthy middle-aged army officers. *Psychosomatics*. 1991;32(3):337–42.

173. Lewis SL, Miner-Williams D, Novian A, Escamilla MI, Blackwell PH, Kretzschmar JH, et al. A stress-busting program for family caregivers. *Rehabil Nurs*. 2009 Jul-Aug;34(4):151–9.
174. Amianto F, Bertorello A, Spalatro A, Milazzo M, Signa C, Cavarero S, et al. Adlerian parental counseling in eating disorders: preliminary data of a controlled clinical trial. *Eat Weight Disord*. 2014;19(3):303–14.
175. Friedman EM, Ruini C, Foy R, Jaros LV, Sampson H, Ryff CD. Lighten UP! A community-based group intervention to promote psychological well-being in older adults. *Aging Ment Heal*. 2017 Feb;21(2):199–205.
176. Baldoni F, Baldaro B, Trombini G. Psychotherapeutic perspectives in urethral syndrome. *Stress Med*. 1995 Jan;11(1):79–84.
177. Fava GA, Rafanelli C, Cazzaro M, Conti S, Grandi S. Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders. *Psychol Med*. 1998 Mar;28(2):475–80.
178. Misri S, Kostaras X, Fox D, Kostaras D. The impact of partner support in the treatment of postpartum depression. *Can J Psychiatry*. 2000 Aug;45(6):554–8.
179. Fava GA, Ruini C, Rafanelli C, Finos L, Salmaso L, Mangelli L, et al. Well-being therapy of generalized anxiety disorder. *Psychother Psychosom*. 2005;74(1):26–30.
180. Ruini C, Belaise C, Brombin C, Caffo E, Fava GA. Well-being therapy in school settings: a pilot study. *Psychother Psychosom*. 2006;75(6):331–6.
181. Ruini C, Ottolini F, Tomba E, Belaise C, Albieri E, Visani D, et al. School intervention for promoting psychological well-being in adolescence. *J Behav Ther Exp Psychiatry*. 2009 Dec;40(4):522–32.
182. Tomba E, Belaise C, Ottolini F, Ruini C, Bravi A, Albieri E, et al. Differential effects of well-being promoting and anxiety-management strategies in a non-clinical school setting. *J Anxiety Disord*. 2010 Apr;24(3):326–33.
183. Martino ML, Freda MF, Camera F. Effects of guided written disclosure protocol on mood states and psychological symptoms among parents of off-therapy acute lymphoblastic leukemia children. *J Health Psychol*. 2013 Jun;18(6):727–36.
184. Kellner R, Neidhardt J, Krakow B, Pathak D. Changes in chronic nightmares after one session

- of desensitization or rehearsal instructions. *Am J Psychiatry*. 1992 May;149(5):659–63.
185. Neidhardt EJ, Krakow B, Kellner R, Pathak D. The beneficial effects of one treatment session and recording of nightmares on chronic nightmare sufferers. *Sleep*. 1992 Oct;15(5):470–3.
 186. Krakow B, Kellner R, Neidhardt J, Pathak D, Lambert L. Imagery rehearsal treatment of chronic nightmares: with a thirty month follow-up. *J Behav Ther Exp Psychiatry*. 1993 Dec;24(4):325–30.
 187. Krakow B, Kellner R, Pathak D, Lambert L. Imagery rehearsal treatment for chronic nightmares. *Behav Res Ther*. 1995 Sep;33(7):837–43.
 188. Monti F, Tonetti L, Ricci Bitti PE. Comparison of cognitive-behavioural therapy and psychodynamic therapy in the treatment of anxiety among university students: an effectiveness study. *Br J Guid Couns*. 2014;42(3):233–44.
 189. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in women. *Am J Cardiol*. 1995 Feb;75(5):340–3.
 190. Lavie CJ, Milani RV. Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort. *Am J Cardiol*. 1995 Jul;76(3):177–9.
 191. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients ≥ 75 years of age. *Am J Cardiol*. 1996 Sep;78(6):675–7.
 192. Lavie CJ, Milani RV. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. *Am J Cardiol*. 1997 Feb;79(4):397–401.
 193. Maines TY, Lavie CJ, Milani RV, Cassidy MM, Gilliland YE, Murgu JP. Effects of cardiac rehabilitation and exercise programs on exercise capacity, coronary risk factors, behavior, and quality of life in patients with coronary artery disease. *South Med J*. 1997 Jan;90(1):43–9.
 194. Milani RV, Lavie CJ. Disparate effects of out-patient cardiac and pulmonary rehabilitation programs on work efficiency and peak aerobic capacity in patients with coronary disease or severe obstructive pulmonary disease. *J Cardiopulm Rehabil*. 1998 Jan-Feb;18(1):17–22.
 195. Lavie CJ, Milani RV. Adverse psychological and coronary risk profiles in young patients with coronary artery disease and benefits of formal cardiac rehabilitation. *Arch Intern Med*. 2006 Sep;166(17):1878–83.

196. Lavie CJ, Milani JN. Do antioxidant vitamins ameliorate the beneficial effects of exercise training on insulin sensitivity? *J Cardiopulm Rehabil Prev.* 2011 Jul-Aug;31(4):211–6.
197. Milani RV, Lavie CJ. Impact of worksite wellness intervention on cardiac risk factors and one-year health care costs. *Am J Cardiol.* 2009 Nov;104(10):1389–92.
198. Michelacci L, Fava GA, Grandi S, Bovicelli L, Orlandi C, Trombini G. Psychological reactions to ultrasound. Examination during pregnancy. *Psychother Psychosom.* 1988;50(1):1–4.
199. Grussu P, Quatraro RM. Maternity blues in Italian primipara women: symptoms and mood states in the first fifteen days after childbirth. *Health Care Women Int.* 2013 Jul;34(7):556–76.
200. Trombini E, Surcinelli P, Piccioni A, Alessandrini R, Faldella G. Environmental factors associated with stress in mothers of preterm newborns. *Acta Paediatr Int J Paediatr.* 2008 Jul;97(7):894–8.
201. Bull MJ, Maruyama G, Luo D. Testing a model for posthospital transition of family caregivers for elderly persons. *Nurs Res.* 1995 May-Jun;44(3):132–8.
202. Grandi S, Fava GA, Cunsolo A, Saviotti FM, Ranieri M, Trombini G, et al. Rating depression and anxiety after mastectomy: observer versus self-rating scales. *Int J Psychiatry Med.* 1990;20(2):163–71.
203. Grassi L, Molinari S. Pattern of emotional control and psychological reactions to breast cancer: a preliminary report. *Psychol Rep.* 1988 Jun;62(3):727–32.
204. Bartolucci G, Savron G, Fava GA, Grandi S, Trombini G, Orlandi C. Psychological reactions to thermography and mammography. *Stress Med.* 1989 Jul-Sep;5(3):195–9.
205. Grassi L, Rosti G, Albertazzi L, Marangolo M. Psychological stress symptoms before and after autologous bone marrow transplantation in patients with solid tumors. *Bone Marrow Transplant.* 1996 May;17(5):843–7.
206. Baldaro B, Gentile G, Codispoti M, Mazzetti M, Trombini E, Flamigni C. Psychological distress of conservative and nonconservative uterine surgery: a prospective study. *J Psychosom Res.* 2003 Apr;54(4):357–60.
207. Moore-West M, Harrington DL, Mennin SP, Kaufman A, Skipper BJ. Distress and attitudes toward the learning environment: effects of a curriculum innovation. *Teach Learn Med.* 1989;1(3):151–7.
208. Stewart DW, de Vries J, Singer DL, Degen GG, Wener P. Canadian dental students' perceptions of their learning environment and psychological functioning over time. *J Dent*

Educ. 2006 Sep;70(9):972–81.

209. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961 Jun;4(6):561–71.
210. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. *Anesth Analg*. 1998 Jan;86(1):102–6.
211. Ryff CD. Happiness is everything, or is it? Explorations on the meaning of psychological well-being. *J Pers Soc Psychol*. 1989;57(6):1069–81.
212. Reynolds CR, Richmond BO. What I think and feel: a revised measure of children's manifest anxiety. *J Abnorm Child Psychol*. 1978 Jun;6(2):271–80.
213. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol*. 1959;32(1):50–5.
214. Giusti M, Meineri I, Malagamba D, Cuttica CM, Fattacciu G, Menichini U, et al. Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. *Eur J Clin Invest*. 1998 Jan;28(1):13–9.
215. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. *J Psychiatr Res*. 2005 Jan;39(1):43–53.
216. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960 Feb;23(1):56–62.
217. Paykel ES. The clinical interview for depression. Development, reliability and validity. *J Affect Disord*. 1985 Jul;9(1):85–96.
218. Guidi J, Fava GA, Bech P, Paykel E. The clinical interview for depression: a comprehensive review of studies and clinimetric properties. *Psychother Psychosom*. 2011;80(1):10–27.
219. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Services; 1971.
220. Briere J. Trauma Symptom Inventory professional manual. Lutz, FL: Psychological Assessment Resources; 1995.
221. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. *Behav Sci*. 1974 Jan;19(1):1–15.
222. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general

- population. *Appl Psychol Meas*. 1977 Jun;1(3):385–401.
223. Gambetti E, Bensi L, Nori R, Giusberti F. The trauma symptom inventory: Italian validation of an instrument for the assessment of post-traumatic symptoms. *Epidemiol Psychiatr Sci*. 2011 Dec;20(4):345–55.
 224. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983 Dec;24(4):385–96.
 225. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979 Apr;134:382–9.
 226. Kellner R. The Brief Depression Rating Scale. In: Sartorius N, Ban TA, editors. *Assessment of depression*. Berlin, Heidelberg: Springer Berlin Heidelberg; 1986. pp. 179–87.
 227. Derogatis LR, Allgood A, Auerbach P, Eubank D, Greist J, Bharmal M, et al. Validation of a Women's Sexual Interest Diagnostic Interview - Short Form (WSID-SF) and a Daily Log of Sexual Activities (DLSA) in postmenopausal women with hypoactive sexual desire disorder. *J Sex Med*. 2010 Feb;7(2 Pt 2):917–27.
 228. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. *Psychiatry Res*. 2007 Jan;149(1–3):195–200.
 229. Worthington J, Fava M, Agustin C, Alpert J, Nierenberg AA, Pava JA, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients: relationship with response to treatment. *Psychosomatics*. 1996 Nov-Dec;37(6):518–22.
 230. Iosifescu DV, Nierenberg AA, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. *Psychosomatics*. 2004 Sep-Oct;45(5):419–25.
 231. Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, et al. Tissue type-specific bioenergetic abnormalities in adults with major depression. *Neuropsychopharmacology*. 2017 Mar;42(4):876–85.
 232. Choi J, Jeong B, Rohan ML, Polcari AM, Teicher MH. Preliminary evidence for white matter tract abnormalities in young adults exposed to parental verbal abuse. *Biol Psychiatry*. 2009 Feb;65(3):227–34.
 233. Perlis RH, Holt DJ, Smoller JW, Blood AJ, Lee S, Kim BW, et al. Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy

participants. *Arch Gen Psychiatry*. 2008 Aug;65(8):882–92.

234. Fava M, Abraham M, Pava J, Shuster J, Rosenbaum J. Cardiovascular risk factors in depression: the role of anxiety and anger. *Psychosomatics*. 1996 Jan-Feb;37(1):31–7.
235. Teicher MH, Samson JA, Polcari A, McGreenery CE. Sticks, stones, and hurtful words: relative effects of various forms of childhood maltreatment. *Am J Psychiatry*. 2006 Jun;163(6):993–1000.
236. Teicher MH, Samson JA, Sheu YS, Polcari A, McGreenery CE. Hurtful words: association of exposure to peer verbal abuse with elevated psychiatric symptom scores and corpus callosum abnormalities. *Am J Psychiatry*. 2010 Dec;167(12):1464–71.
237. Teicher MH, Vitaliano GD. Witnessing violence toward siblings: an understudied but potent form of early adversity. *PLoS One*. 2011;6(12):e28852.
238. Khan A, McCormack HC, Bolger EA, McGreenery CE, Vitaliano G, Polcari A, et al. Childhood maltreatment, depression, and suicidal ideation: critical importance of parental and peer emotional abuse during developmental sensitive periods in males and females. *Front Psychiatry*. 2015;6:42.
239. Próspero M. The effect of coercion on aggression and mental health among reciprocally violent couples. *J Fam Violence*. 2008 Apr;23(3):195–202.
240. Próspero M. Sex-Symmetric effects of coercive behaviors on mental health?: not exactly. *J Interpers Violence*. 2009 Jan;24(1):128–46.
241. Próspero M, Kim M. Mutual partner violence: mental health symptoms among female and male victims in four racial/ethnic groups. *J Interpers Violence*. 2009 Dec;24(12):2039–56.
242. Próspero M, Fawson P. Sexual coercion and mental health symptoms among heterosexual men: the pressure to say “yes.” *Am J Mens Health*. 2010 Jun;4(2):98–103.
243. Kellner R, Slocumb J, Wiggins RG, Abbott PJ, Winslow WW, Pathak D. Hostility, somatic symptoms, and hypochondriacal fears and beliefs. *J Nerv Ment Dis*. 1985 Sep;173(9):554–60.
244. Demopulos C, Fava M, Mclean NE, Alpert JE, Nierenberg AA, Rosenbaum JF. Hypochondriacal concerns in depressed outpatients. *Psychosom Med*. 1996 Jul-Aug;58(4):314–20.
245. Otto MW, Demopulos CM, McLean NE, Pollack MH, Fava M. Additional findings on the association between anxiety sensitivity and hypochondriacal concerns: examination of patients with major depression. *J Anxiety Disord*. 1998 May-Jun;12(3):225–32.

246. Sirri L, Pierangeli G, Cevoli S, Cortelli P, Grandi S, Tossani E. Illness perception in patients with migraine: an exploratory study in a tertiary care headache centre. *J Psychosom Res.* 2018 Aug;111:52–7.
247. Grandi S, Sirri L, Wise TN, Tossani E, Fava GA. Kellner's emotional inhibition scale: a clinimetric approach to alexithymia research. *Psychother Psychosom.* 2011;80(6):335–44.
248. Andrei F, Smith MM, Surcinelli P, Baldaro B, Saklofske DH. The Trait Emotional Intelligence Questionnaire: internal structure, convergent, criterion, and incremental validity in an Italian sample. *Meas Eval Couns Dev.* 2016;49(1):34–45.
249. Otto MW, Pollack MH, Fava M, Uccello R, Rosenbaum JF. Elevated Anxiety Sensitivity Index scores in patients with major depression: correlates and changes with antidepressant treatment. *J Anxiety Disord.* 1995 Mar-Apr;9(2):117–23.
250. Gupta D, Pérez-Edgar K. The role of temperament in somatic complaints among young female adults. *J Health Psychol.* 2012 Jan;17(1):26–35.
251. Yeh PM, Bull M. Influences of spiritual well-being and coping on mental health of family caregivers for elders. *Res Gerontol Nurs.* 2009 Jul;2(3):173–81.
252. Sirri L, Magelli C, Grandi S. Predictors of perceived social support in long-term survivors of cardiac transplant: the role of psychological distress, quality of life, demographic characteristics and clinical course. *Psychol Heal.* 2011 Jan;26(1):77–94.
253. Sirri L, Ricci Garotti MG, Grandi S, Tossani E. Adolescents' hypochondriacal fears and beliefs: relationship with demographic features, psychological distress, well-being and health-related behaviors. *J Psychosom Res.* 2015 Oct;79(4):259–64.
254. Salovey P, Stroud LR, Woolery A, Epel ES. Perceived emotional intelligence, stress reactivity, and symptom reports: Further explorations using the trait meta-mood scale. *Psychol Heal.* 2002;17(5):611–27.
255. Clough DH. The effects of cognitive distortion and depression on disability in rheumatoid arthritis. *Res Nurs Health.* 1991 Dec;14(6):439–46.
256. Jette DU, Downing J. The relationship of cardiovascular and psychological impairments to the impairments to the health status of patients enrolled in cardiac rehabilitation programs. *Phys Ther.* 1996 Feb;76(2):130–9.
257. Sirri L, Potena L, Masetti M, Tossani E, Magelli C, Grandi S. Psychological predictors of mortality in heart transplanted patients: a prospective, 6-year follow-up study. *Transplantation.*

2010 Apr;89(7):879–86.

258. Rafanelli C, Gostoli S, Tully PJ, Roncuzzi R. Hostility and the clinical course of outpatients with congestive heart failure. *Psychol Heal*. 2016;31(2):228–38.
259. Alton ME, Zeng Y, Tough SC, Mandhane PJ, Kozyrskyj AL. Postpartum depression, a direct and mediating risk factor for preschool wheeze in girls. *Pediatr Pulmonol*. 2016 Apr;51(4):349–57.
260. Tough SC, Siever JE, Leew S, Johnston DW, Benzies K, Clark D. Maternal mental health predicts risk of developmental problems at 3 years of age: follow up of a community based trial. *BMC Pregnancy Childbirth*. 2008 May;8(1):16.
261. Alton ME, Tough SC, Mandhane PJ, Kozyrskyj AL. Street drug use during pregnancy: potential programming effects on preschool wheeze. *J Dev Orig Health Dis*. 2013 Apr;4(2):191–9.
262. Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. *Psychiatry Res*. 2004 May;126(3):287–90.
263. Bodkin JA, Allgulander C, Llorca PM, Spann ME, Walker DJ, Russell JM, et al. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder. *Hum Psychopharmacol*. 2011 Apr;26(3):258–66.
264. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. *Psychother Psychosom*. 1998 Jul-Oct;67(4–5):266–70.
265. Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, et al. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. *J Clin Psychiatry*. 2004 Apr;65(4):543–6.
266. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, et al. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. *Psychiatry Res*. 2008 Oct;161(1):116–20.
267. Kellner R. Improvement criteria in drug trials with neurotic patients. Part 1. *Psychol Med*. 1971 Nov;1(5):416–25.
268. Kellner R. The measurement of depression and anxiety. In: den Boer JA, Sitsen JMA, editors. *Handbook of Depression and Anxiety*. New York: Dekker; 1994. p. 133–58.

269. Glass RM, Uhlenhuth EH, Kellner R. The value of self-report assessment in studies of anxiety disorders. *J Clin Psychopharmacol*. 1987 Aug;7(4):215–21.
270. Bech P. *Clinical Psychometrics*. Oxford: Wiley-Blackwell; 2012.
271. Guidi J, Brakemeier EL, Bockting CLH, Cosci F, Cuijpers P, Jarrett RB, et al. Methodological recommendations for trials of psychological interventions. *Psychother Psychosom*. 2018;87(5):276–84.
272. Contreras A, Nieto I, Valiente C, Espinosa R, Vazquez C. The study of psychopathology from the network analysis perspective: a systematic review. *Psychother Psychosom*. 2019;88(2):71–83.
273. Fava GA, Rafanelli C. Iatrogenic factors in psychopathology. *Psychother Psychosom*. 2019;88(3):129–40.
274. Piolanti A, Gostoli S, Gervasi J, Sonino N, Guidi J. A trial integrating different methods to assess psychosocial problems in primary care. *Psychother Psychosom*. 2019;88(1):30–6.
275. Guidi J, Piolanti A, Gostoli S, Schamong I, Brakemeier E-L. Mental pain and euthymia as transdiagnostic clinimetric indices in primary care. *Psychother Psychosom*. 2019; 88 (6):252–253.

Table 1. SQ scales and subscales

Scales (92 items)	Symptom subscales (68 items)	Well-being subscales (24 items)
Depression	Depression (e.g., Item 6. <i>Sad, blue</i> ; Item 61. <i>Not interested in things</i>)	Contentment (e.g., Item 4. <i>Cheerful</i> ; Item 7. <i>Happy</i>)
Anxiety	Anxiety (e.g., Item 1. <i>Nervous</i> ; Item 36. <i>Scared</i>)	Relaxation (e.g., Item 9. <i>Feeling calm</i> ; Item 29. <i>Relaxed</i>)
Hostility	Hostility (e.g., Item 3. <i>Irritable</i> ; Item 20. <i>Angry</i>)	Friendliness (e.g., Item 13. <i>Feeling kind toward people</i> ; Item 35. <i>Patient</i>)
Somatization	Somatization (e.g., Item 12. <i>Feeling of not enough air</i> ; Item 77. <i>Muscle pains</i>)	Physical well-being (e.g., Item 10. <i>Feeling healthy</i> ; Item 19. <i>No pains anywhere</i>)

